Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
Go back to Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026| Aperture Health, Inc. (NASDAQ: APRE) | Delayed: 0.84 +0.05 (6.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.79 | 52 Week High | $0.08 | |||
| Open | $0.84 | 52 Week Low | $0.00 | |||
| Day High | $0.88 | P/E | N/A | |||
| Day Low | $0.78 | EPS | $0.00 | |||
| Volume | 317,743 | |||||
